Achillion Pharmaceuticals Inc. shares fell in the extended session Tuesday after the drug developer reported promising early data on one of its kidney-disease treatments but said a large stakeholder was selling shares in a secondary offering. Achillion shares fell 9.2% to $3.35 after hours. Achillion said Johnson & Johnson Inc.’s venture capital arm, Johnson & Johnson Innovation-JJDC Inc., will sell 18.4 million shares of Achillion in a public offering and that Achillion would not receive proceeds. Achillion has 136.9 million shares outstanding. Separately, the company said early data from its mid-stage clinical trial for ACH-4471 showed the drug reduced protein in the urine by more than 50% in patients with C3 glomerulopathy, a rare disease where protein deposits build up in the kidneys.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News